Do CSF biomarkers and FDG PET imaging show sufficient clinical utility for diagnosis of dementia subtypes?


No Thumbnail Available
Type
Article
Change log
Authors
Smailagic, Nadja 
Brayne, CEG 
Abstract

NICE recently published updated recommendations for diagnosing dementia and how people with this clinical syndrome navigate the care system. In this update, major changes from the previous version include the use of emerging diagnostic methods in research. NICE recommendations regarding the use of CSF biomarkers and FDG PET imaging for diagnosing dementia subtypes in specialist clinical setting are based on results from diagnostic test accuracy (DTA) studies identified and included in a systematic review conducted according to Cochrane DTA Handbook guidelines (http://methods.cochrane.org/sdt/handbook-dta-reviews). We have concerns about the way in which the evidence has been translated into practice recommendations.

Description
Keywords
Journal Title
BMJ: British Medical Journal
Conference Name
Journal ISSN
0959-535X
Volume Title
361
Publisher
BMJ
Sponsorship
Paul G Allen Family Foundation (12076)
During the development of this work, JP was an employee of NICE, which is commissioned and funded by the Department of Health to develop clinical guidelines. No authors received specific funding to write this summary.